Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
247.10 418.30 206.30 4.60 16.80 6.80 11.60 3.30 (26.80) (28.88)
Depreciation & Amortization
90.40 80.80 72.80 63.20 57.40 55.40 27.90 15.60 13.90 13.83
Non Cash Items (Other)
254.90 (51.70) 57.30 53.70 121.30 85.20 78.60 69.80 52.50 44.54
Accounts Receivable Change
(140.20) (10.40) (154.20) (51.80) (71.30) (13.70) (10.90) (14.60) (26.30) 12.55
Change in inventories
(10.60) (32.40) (53.60) (49.10) (154.40) (50.50) (30.20) (38.80) 1.70 (24.10)
Accounts Payable Change
— 2.20 (11.00) (2.40) (15.60) — — — — —
Change in payables and accrued liability
209.40 47.70 59.30 137.60 24.40 34.90 43.30 20.50 27.30 0.64
Change in other assets and liabilities
(81.70) (21.90) (42.10) (36.80) (46.70) (34.10) (21.90) (19.90) (1.00) (2.67)
Operating Cash Flow
569.30 430.20 145.70 119.00 (68.10) 84.00 98.40 35.90 41.30 15.91
Capital expenditures
(191.60) (124.90) (75.60) (122.90) (111.90) (129.00) (163.70) (157.40) (73.80) (22.11)
Change in intangibles (net)
(27.80) (9.10) (33.60) (34.40) (10.80) (37.50) (7.20) (5.00) (3.40) —
Net Aquisitions
— — — (26.00) — — — — — 5.71
Short Term Investments Change (Net)
— (12.20) (7.20) (7.80) 40.00 180.50 97.30 (22.10) (133.60) (161.61)
Other investing activities
(3.20) — (3.00) (16.80) (28.20) (32.00) (8.60) (17.78) (4.05) (2.87)
Investing cash flow
(222.70) (146.20) (119.40) (191.10) (82.70) 14.00 (73.60) (184.50) (210.80) (178.01)
Repayment/Issuance of Debt (Net)
(647.20) (38.20) (24.80) (39.80) 51.90 58.60 116.60 (6.70) 292.80 174.58
Equity Repurchase (Common, Net)
138.90 20.10 26.90 16.30 23.50 509.20 (34.50) 15.80 15.80 4.85
Other financial activities
(86.80) (10.00) (15.70) (16.80) (34.70) 37.70 (8.60) (17.80) (4.10) (2.87)
Financing cash flow
(595.30) (28.00) (13.60) (40.30) 40.70 605.50 73.50 (8.70) 304.50 176.57
Exchange Rate Adjustment
11.50 (6.80) 1.80 (4.30) (5.50) 4.80 1.50 (1.40) 0.40 0.03
Change in Cash
(237.30) 249.20 14.40 (116.70) (115.60) 708.30 99.80 (158.70) 135.40 14.50
Beginning Cash
953.40 704.20 689.80 806.40 922.00 213.70 113.90 272.60 137.20 122.67
Ending Cash
716.10 953.40 704.20 689.70 806.40 922.00 213.70 113.90 272.60 137.17
Stock Based Compensation
62.70 69.30 48.40 40.90 34.40 35.90 28.70 37.50 31.90 23.62
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(23.10) (17.00) (190.60) (2.50) (263.60) (63.40) (19.70) (52.80) 1.70 (13.58)
Investments Change (Net)
— (12.20) (7.20) (7.80) 40.00 180.50 97.30 (22.10) (133.60) (161.61)
Issuance/Purchase of Shares
138.90 20.10 26.90 16.30 23.50 509.20 (34.50) 15.80 15.80 4.85
Other line items
Revenue per Employee
0.50 0.53 0.57 0.50 0.48 0.48 0.55 0.48 0.54 0.57

Fold the line items

In millions of $ except per-share values · columns are period end dates